Get the free weekly contract digest
The latest new contracts, like The AbbVie Foundation and MATTER’s — who’s behind them and what they mean, delivered to your inbox every week. No credit card, unsubscribe anytime.
New new contracts, summarized for you
No login, no app to check — it comes to you
See who's moving and how much in your market
Contract Type
partnership
ChicagoHealth CareNon ProfitDescription
AbbVie, a global biopharmaceutical company, has announced a collaboration with EvolveImmune Therapeutics, specializing in immunotherapy, to develop novel antibody-based therapies targeting solid and hematologic malignancies. The collaboration involves an option-to-license agreement and aims to utilize EvolveImmune's proprietary EVOLVE T-cell engager platform to enhance T-cell responses against tumors, addressing unmet needs in cancer treatment.